科研之友
微信
新浪微博
Facebook
分享链接
摘要
To assess the ability of magnetic resonance enterography global score (MEGS) to characterise Crohn's disease (CD) response to anti-TNF-alpha therapy. Thirty-six CD patients (median age 26 years, 20 males) commencing anti-TNF-alpha therapy with concomitant baseline MRI enterography (MRE) were identified retrospectively. Patients' clinical course was followed and correlated with subsequent MREs. Scan order was randomised and MEGS (a global activity score) was applied by two blinded radiologists. A physician's global assessment of the disease activity (remission, mild, moderate or severe) at the time of MRE was assigned. The cohort was divided into clinical responders and non-responders and MEGS compared according to activity status and treatment response. Interobserver agreement was assessed. Median MEGS decreased significantly between baseline and first follow-up in responders (28 versus 6, P < 0.001) but was unchanged in non-responders (26 versus 18, P = 0.28). The median MEGS was significantly lower in clinical remission (9) than in moderate (14) or severe (29) activity (P < 0.001). MEGS correlated significantly with clinical activity (r = 0.53; P < 0.001). Interobserver Bland-Altman limits of agreement (BA LoA) were -19.7 to 18.5. MEGS decreases significantly in clinical responders to anti-TNF-alpha therapy but not in non-responders, demonstrates good interobserver agreement and moderate correlation with clinical disease activity. aEuro cent MRI scores of Crohn's activity are used increasingly in clinical practice and therapeutic trials. aEuro cent Such scores have been advocated as biomarkers of therapeutic response. aEuro cent MEGS reflects clinical response to anti-TNF-alpha therapy and the clinical classification of disease activity. aEuro cent MEGS demonstrates good interobserver agreement.
- 出版日期2016-7
